Latest Racing News

Kinterra has increased its takeover offer for New World Resources to A$0.062 per share, positioning its bid as superior and less conditional than rival Central Metals Asia’s scheme proposal. With a significant stake and strategic moves underway, the battle for NWR ownership intensifies.

Titomic’s Netherlands division has secured €800,000 in funding from the Dutch 3D Print Kompas program to advance its Cold Spray Additive Manufacturing technology, aiming to expand R&D and industrial applications across Europe.

Sports Entertainment Group upgrades its FY25 EBITDA forecast to $9m-$10m, driven by strategic divestments and new media initiatives, setting the stage for continued growth in FY26.

Canyon Resources has secured a significant credit facility and advanced key contracts, setting the stage for production and first bauxite shipments from its Minim Martap project in early 2026.

PointsBet shareholders have voted in favour of the proposed $1.20 per share acquisition by MIXI, Inc, marking a significant premium and clearing a key hurdle ahead of court approval.

Victory Metals has landed a US$10 million unsecured loan from Saudi Arabia’s sovereign wealth fund, marking a strategic boost for its North Stanmore rare earths project in Western Australia.

Microba Life Sciences has raised $14.5 million to accelerate clinical adoption of its microbiome testing products, while narrowing its FY25 revenue guidance and signing a strategic UK laboratory agreement.

Ionic Rare Earths is advancing plans for multiple magnet recycling plants in the US, leveraging patented technology to produce high-purity rare earth oxides amid growing demand for sovereign supply chains.

PointsBet Holdings has highlighted that Betr Entertainment’s proposed takeover offer undervalues its shares compared to MIXI Australia’s superior $1.20 cash bid, intensifying the takeover battle.

Symal Group is poised to exceed its FY2025 EBITDA forecast, driven by strong project execution and a robust pipeline of contracts and acquisitions.

Race Oncology has successfully dosed the first patient with its RC220 and doxorubicin combination in a Phase 1 trial for advanced solid tumours, reporting no dose-limiting side effects. This milestone marks a key step in evaluating the safety and potential cardioprotective benefits of the novel therapy.

Everest Metals has been accepted into the US Defence Industrial Base Consortium, unlocking strategic collaboration and funding opportunities for its Mt Edon Rubidium Project in Western Australia. This milestone advances Australia’s first commercial rubidium production, addressing critical global supply shortages.